Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era

Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitor ◽

Second Line ◽

Phase 2 ◽

Antiangiogenic Treatment ◽

Phase 2 Trial

Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma

Anticancer Research ◽

10.21873/anticanres.11480 ◽

2017 ◽

Vol 37 (3) ◽

pp. 1523-1528

Keyword(s):

Renal Cell Carcinoma ◽

Targeted Therapy ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Renal Cell ◽

Molecular Targeted Therapy ◽

Kinase Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Second Line

SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.4500 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4500-4500 ◽

Cited By ~ 23

Author(s):

R. J. Motzer ◽

B. I. Rini ◽

M. D. Michaelson ◽

B. G. Redman ◽

G. R. Hudes ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Antitumor Activity ◽

Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitor ◽

Second Line ◽

Phase 2 ◽

Second Line Therapy ◽

Phase 2 Trial ◽

Line Therapy

SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.4500 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4500-4500 ◽

Cited By ~ 5

Author(s):

R. J. Motzer ◽

B. I. Rini ◽

M. D. Michaelson ◽

B. G. Redman ◽

G. R. Hudes ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Antitumor Activity ◽

Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitor ◽

Second Line ◽

Phase 2 ◽

Second Line Therapy ◽

Phase 2 Trial ◽

Line Therapy

Comparison of Axitinib and Everolimus in the Second Line Treatment of Metastatic Renal Cell Carcinoma Following Previous Treatment with a Tyrosine Kinase Inhibitor: a Multicentre Retrospective Analysis

Clinical Oncology ◽

10.1016/j.clon.2015.12.022 ◽

2016 ◽

Vol 28 (5) ◽

pp. e15-e16

Author(s):

S. Iqbal ◽

W. Badreldin ◽

S. Sundar ◽

N. Thompson ◽

J. Tanguay

Keyword(s):

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Retrospective Analysis ◽

Renal Cell ◽

Kinase Inhibitor ◽

Previous Treatment ◽

Line Treatment ◽

Second Line

A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

Cancer ◽

10.1002/cncr.28634 ◽

2014 ◽

Vol 120 (11) ◽

pp. 1647-1655 ◽

Cited By ~ 24

Author(s):

Jorge A. Garcia ◽

Gary R. Hudes ◽

Toni K. Choueiri ◽

Walter M. Stadler ◽

Laura S. Wood ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Disease Progression ◽

Renal Cell ◽

Kinase Inhibitor ◽

Phase 2 ◽

Tyrosine Kinase Inhibitor Therapy

Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e16129 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e16129-e16129

Author(s):

Emilio Esteban ◽

Xavier Garcia del Muro ◽

Juan Manuel Sepúlveda ◽

Pablo Maroto ◽

Enrique Gallardo Diaz ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Phase Ii ◽

Renal Cell ◽

Kinase Inhibitor ◽

Phase Ii Study ◽

Second Line ◽

Previously Treated

A Case of Metastatic Renal Cell Carcinoma to the Maxillary Sinus Treated with Tyrosine Kinase Inhibitor

Korean Journal of Otorhinolaryngology - Head and Neck Surgery ◽

10.3342/kjorl-hns.2012.55.11.717 ◽

2012 ◽

Vol 55 (11) ◽

pp. 717 ◽

Cited By ~ 2

Author(s):

Young Hyo Kim ◽

Jae Eun Kim ◽

Sungmin Park ◽

Tae Young Jang

Keyword(s):

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Maxillary Sinus ◽

Renal Cell ◽

Kinase Inhibitor

Faculty Opinions recommendation of Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717979900.793471988 ◽

2013 ◽

Author(s):

Hendrik van Poppel ◽

Yuri Tolkach

Keyword(s):

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Renal Cell ◽

Kinase Inhibitor ◽

Patient Survival ◽

Cytoreductive Nephrectomy

Pegilodecakin as monotherapy or in combination with anti‐PD ‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study

International Journal of Cancer ◽

10.1002/ijc.33556 ◽

2021 ◽

Author(s):

Nizar M. Tannir ◽

Kyriakos P. Papadopoulos ◽

Deborah J. Wong ◽

Raid Aljumaily ◽

Annie Hung ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Phase I ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase I Study ◽

Kinase Inhibitor ◽

Heavily Pretreated ◽

Pretreated Patients

Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-015-2942-1 ◽

2015 ◽

Vol 77 (2) ◽

pp. 339-347 ◽

Cited By ~ 3

Author(s):

Dong-Hoe Koo ◽

Inkeun Park ◽

Jin-Hee Ahn ◽

Dae-Ho Lee ◽

Dalsan You ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Tyrosine Kinase Inhibitor Discontinuation

Renal Cell ◽

Kinase Inhibitor ◽

Long Term Outcomes ◽